Patient-Derived Xenograft Model Market is expected to reach US$ 975.31 million by 2030

Other Tumor Models Segment to Lead Patient-Derived Xenograft Model Market Based on Tumor Type During 2022–2030

According to our new research study on “Patient-Derived Xenograft Model Market Forecast to 2030 – Global Analysis – by Model Type, Tumor Type, Application, End User, and Geography,” the market was valued at US$ 378.46 million in 2022. The patient-derived xenograft model market size is projected to reach US$ 975.31 million by 2030, and the market is expected to register a CAGR of 12.6% from 2022 to 2030. Key factors driving the market's growth include the growing awareness of humanized PDX models and the rising demand for personalized medicine. However, significant operational costs associated with these models hinder the growth of the market.

Patient-Derived Xenograft Model Market Analysis Based on the Segment:

Based on model type, the market is bifurcated into mice models and rats models. In 2022, the mice models segment held a significant patient-derived xenograft model market share. In addition, the segment is expected to register the highest CAGR during 2022–2030.

Patient-Derived Xenograft Model Market, by Region, 2022(%)

Source: The Insight Partners Analysis

Based on tumor type, the patient-derived xenograft model market is segmented into gastrointestinal tumor models, respiratory tumor models, gynecological tumor models, and other tumor models. In 2022, the other tumor models segment held a significant patient-derived xenograft model market share. It is anticipated to record the fastest CAGR during the forecast period. Other tumor models consist of breast cancer, lung cancer, prostate cancer, and colorectum cancer. According to the American Society of Clinical Oncology, colorectal cancer is the third most commonly detected cancer in both men and women in the US. According to their estimates, new colorectal cancer diagnoses in adults in 2023 were set to reach the count of ~153,020 in the US. In 2020, Japan reported 148,505 colorectal cancer cases, according to World Cancer Research Fund International.

As per the World Health Organization (WHO), ~2.3 million females were diagnosed with breast cancer globally, and 685,000 deaths caused by the disease were reported in 2020. According to the Centers for Disease Control and Prevention, in 2020, ~239,612 new cases of breast cancer were reported among women in the US, while ~42,273 women suffering from this disease succumbed to death. As per the National Health Service (NHS) data, ~1 in 7 women are diagnosed with breast cancer during their lifespan in Great Britain. Each year, ~55,000 women are diagnosed with breast cancer.

The growing burden of various cancer types creates a strong demand for personalized medicine as well as effective drug discovery and development projects. As cancer is a condition associated with highly complex development mechanisms, the development of effective diagnoses and treatments against it requires a deeper understanding of tumor biology. Patient-derived xenograft models act as a valuable tool for studying tumor behavior and response to different therapies and identifying potential biomarkers. This knowledge gained by using these models contributes to the development of cancer treatment, thereby supporting the segment's growth in the patient-derived xenograft model market.

Based on geography, the patient-derived xenograft model market report is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is anticipated to register the highest CAGR in the market from 2022 to 2030. The rising burden of cancer in the region, advancements in precision medicine, increasing investments in biomedical research, and surging pharmaceutical research and development spending are projected to support the Asia Pacific patient-derived xenograft model market growth during the forecast period. China and Japan are the major contributors to the growth of the market in the region.

According to the WHO, Japan reported 1,028,658 new cancer cases in 2020, and lung cancer was one of the leading types, with 138,532 new cases reported in 2020. Per the same source, the country reported 92,024 new breast cancer cases in 2020, representing 8.9% of the total cancer cases. 17,081 people who have breast cancer succumbed to death in 2020 in Japan.

China accounted for 24% of new diagnoses and 30% of cancer-related fatalities in the world in 2020, as per Centers for Disease Control and Prevention statistics published in April 2023. The age-standardized incidence of breast cancer climbed from 17.07 per 100,000 in 1990 to 35.61 per 100,000 in 2019.

Mice models are essential for investigating disease mechanisms and marking potential drug targets. More than 18,500 strains of mice are available for research communities at the National Resource Center for Mutant Mice (NRCMM) in China, which is affiliated with Nanjing University's Model Animal Research Center and Gempharmatech Company. President Xi Jinping's drive to make the country a biomedical powerhouse by 2025 has propelled the country deeper into drug discovery and genetics, favoring the patient-derived xenograft model market growth.

In Japan, mice models have increasingly become the preferred tool for investigating the mechanisms of pathogenesis, drug discovery, and translational studies. According to Statista, the value of the Japanese personalized medicine industry was estimated at ~US$ 6.45 billion in 2019 and is expected to reach a market size of ~US$ 7.15 billion in 2023. Japan has several research-based pharmaceutical companies that operate globally, including Takeda, Astellas, Daiichi Sankyo, and Dainippon Sumitomo. The market for biologics such as antibodies, protein-based drugs, and vaccines has also grown in the country. Thus, the above-mentioned factors favor the market growth in the region during the forecast period. Moreover, the patient-derived xenograft model market trends include the development of next-generation PDX technologies and ongoing research studies for drug development.  

Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation are among the leading companies profiled in the patient-derived xenograft model market report. 

Based on model type, the patient-derived xenograft model market is categorized into mice models and rats models. Based on tumor type, the market is classified into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, and other tumor models. The market is segmented by application into preclinical drug development, biomarker analysis, translational research, and biobanking. In terms of end user, the market is categorized into pharmaceutical and biotechnology companies, academic and government research institutions, and contract research organizations. Based on geography, the patient-derived xenograft model market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com